Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 161-164

  Yoshida, Hiroshi ^a   Shoda, Toru ^a   Yanai, Hidekatsu ^b   Ikewaki, Katsunori ^c   Kurata, Hideaki ^d   Ito, Kumie ^a   Furutani, Nobuyuki ^a   Tada, Norio ^a   Witztum, Joseph L ^e   Tsimikas, Sotirios ^e  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Konodai National Medical Center   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d Jikei University School of Medicine   (Japan)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Biomarkers; Cardiovascular disease; Lp PLA2; MDA LDL; OxPL apoB; Statin

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; BIOLOGICAL MARKER; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PHOSPHOLIPASE A2; PITAVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID OXIDATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

BIOLOGICAL MARKERS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PROSPECTIVE STUDIES; PYRROLES; QUINOLINES;

EID: 84871360826     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.069     Document Type: Article

References (15)

1. Baigent C., Blackwell L., Emberson J., et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
2. Liao J.K., Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol 2005, 45:89-118.
3. Steinberg D., Witztum J.L. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 30:2311-2316.
4. Yoshida H., Kisugi R. Mechanisms of LDL oxidation. Clin Chim Acta 2010, 411:1875-1882.
5. Taleb A., Witztum J.L., Tsimikas S. Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med 2011, 5:673-694.
6. van Dijk R.A., Kolodgie F., Ravandi A., et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012, 53:2773-2790.
7. Shigematsu S., Takahashi N., Hara M., Yoshimatsu H., Saikawa T. Increased incidence of coronary in-stent restenosis in type 2 diabetic patients is related to elevated serum malondialdehyde-modified low-density lipoprotein. Circ J 2007, 71:1697-1702.
8. Tsimikas S., Miller Y.I. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des 2011, 17:27-37.
9. Weismann D., Hartvigsen K., Lauer N., et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011, 478:76-81.
10. Hiro T., Kimura T., Morimoto T., JAPAN-ACS Investigators, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009, 54:293-302.
11. Hirano T., Ito Y., Koba S., et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 2004, 24:558-563.
12. Arai K., Orsoni A., Mallat Z., et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res 2012, 53:1670-1678.
13. Yoshida H., Ishikawa T., Nakamura H. Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1997, 17:1438-1446.
14. Tanaga K., Bujo H., Inoue M., et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 2002, 22:662-666.
15. Movva R., Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008, 54:788-800.